Stifel Financial Corp Sells 866 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Stifel Financial Corp cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,961 shares of the biopharmaceutical company’s stock after selling 866 shares during the period. Stifel Financial Corp’s holdings in Ultragenyx Pharmaceutical were worth $1,164,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RARE. Millennium Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 103.8% in the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock valued at $76,065,000 after purchasing an additional 942,529 shares during the period. Alkeon Capital Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 34.3% in the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock worth $167,301,000 after acquiring an additional 769,884 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at $17,468,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Ultragenyx Pharmaceutical by 63.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 830,375 shares of the biopharmaceutical company’s stock valued at $34,128,000 after acquiring an additional 323,280 shares during the last quarter. Finally, Ikarian Capital LLC purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at approximately $9,943,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. This represents a 7.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares of the company’s stock, valued at $109,785,600. This trade represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Trading Up 1.7 %

Shares of RARE opened at $44.22 on Monday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $37.02 and a twelve month high of $60.37. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of -6.83 and a beta of 0.56. The firm’s fifty day simple moving average is $49.53 and its 200-day simple moving average is $49.36.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.23) earnings per share. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wells Fargo & Company upped their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. HC Wainwright raised their target price on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $88.46.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.